Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Rise in RSV levels sparks HPA warning

The levels of activity of respiratory syncytial virus (RSV) in England and Wales have risen to the level at which GPs should consider prescribing prophylactic antivirals to at-risk children, the Health Protection Agency has warned.

The past few weeks has seen a sharp increase in the number of cases of RSV reported to HPA laboratories, with over 400 cases reported in week 45.

This has lead the agency to recommend prophylactic palivizumab for children under two years of age with chronic lung disease with oxygen dependency and infants under six months of age with severe congenital heart disease.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say